[Contribution of radioimmunotherapy to the treatment of lymphoma].
Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin's lymphoma. Only Zevalin (Bayer Schering Pharma) radiolabeled with yttrium 90 ((90)Y) is approved in France for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. This radioimmunotherapeutic agent consists of ibritumomab, a murine anti-CD20 monoclonal antibody, conjugated to the metal chelator tiuxetan for retention of the beta emitter (90)Y. This review presents the concept of RIT. The pharmacological characteristics of [(90)Y]-ibritumomab tiuxetan, the specificity of its preparation and its special precautions for use will be described. The other radionuclides and antibodies in development will also be mentioned.
Rizzo-Padoin
N
N
UF radiopharmacie, service pharmacie, hôpital Lariboisière, groupe hospitalier Lariboisière-F.-Widal, AP-HP, Paris, France. nathalie.padoin@lrb.aphp.fr
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000276:immunology; D002614:Chelating Agents / Q000008:administration & dosage; D017326:Clinical Trials, Phase III as Topic; D016503:Drug Delivery Systems; D005260:Female; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D008297:Male; D015337:Multicenter Studies as Topic; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000532:radiotherapy; D016499:Radioimmunotherapy / Q000009:adverse effects; D016032:Randomized Controlled Trials as Topic; D014018:Tissue Distribution; D015021:Yttrium Radioisotopes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20; D002614:Chelating Agents; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan